MoonLake gains FDA alignment on drug approval pathway for hidradenitis suppurativa treatment

MoonLake Immunotherapeutics announced a significant regulatory milestone: the FDA and company reached alignment on both the submission strategy and proposed labeling for sonelokimab, its drug candidate for hidradenitis suppurativa. This outcome from the final pre-BLA meeting removes a major uncertainty and positions MoonLake to file its Biologics License Application, the formal request for marketing approval. For a clinical-stage biotech, FDA alignment on label strategy is particularly important as it defines the patient population and claims the company can pursue commercially.

The company also released Q1 2026 financial results, though the 8-K references the press release without providing figures. Retail investors should monitor the actual BLA submission timing and any updates on the FDA review timeline once filed. The label strategy details—such as patient population breadth and any restrictions—will be critical to understanding the commercial opportunity if sonelokimab gains approval.